Should You Hold PhaseBio Pharmaceuticals Inc (PHAS) Stock Wednesday?

Wednesday, November 02, 2022 12:00 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Hold PhaseBio Pharmaceuticals Inc (PHAS) Stock Wednesday?

PhaseBio Pharmaceuticals Inc (PHAS) stock is lower by -98.02% over the last 12 months, and the average rating from Wall Street analysts is a Hold. InvestorsObserver’s proprietary ranking system, gives PHAS stock a score of 34 out of a possible 100.

That rank is mainly influenced by a long-term technical score of 0. PHAS's rank also includes a short-term technical score of 5.

PHAS has an Overall Score of 34. Find out what this means to you and get the rest of the rankings on PHAS!

See Full PHAS Report

What's Happening with PHAS Stock Today

PhaseBio Pharmaceuticals Inc (PHAS) stock has fallen -16.63% while the S&P 500 is lower by -0.41% as of 11:59 AM on Wednesday, Nov 2. PHAS is lower by -$0.02 from the previous closing price of $0.10 on volume of 4,338,295 shares. Over the past year the S&P 500 has fallen -17.07% while PHAS is lower by -98.02%. PHAS lost -$2.13 per share in the over the last 12 months. Click Here to get the full Stock Report for PhaseBio Pharmaceuticals Inc stock.